Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.